An advisory panel to the agency voted against the removal this wee,k but agreed to revisit the issue once data from Pfizer's post-marketing study for Chantix (varenicline) is available. The firm is currently conducting a study on 8,000 people comparing Chantix with two other smoking-cessation treatments and a placebo in terms of possible serious neuropsychological effects. Data from the study is expected in the third quarter of 2015. Steve Romano, senior vice president of Pfizer's global innovative pharmaceutical business, told Reuters:
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!